September 16, 2010 19:34 ET

CDEX Announces New Management, New Focus and New Future

TUCSON, AZ--(Marketwire - September 16, 2010) -  CDEX Inc. (OTCBB: CEXI) ( -- We are pleased to announce that Jeff Brumfield has been appointed as the new Chairman of the Board and Chief Executive Officer of CDEX Inc. He brings back to the Company Dr. Wade Poteet as the Chief Science Officer who will be overseeing the development of all new technology, as well as providing oversight of all key employees in the area of research and development. We are also excited to bring back Carey Starzinger. Mr. Starzinger will be providing his expertise in the area of computer science, and Mr. Jim Ryles is back as the chief engineer who will be responsible for the design and final production of all products. We are also very excited to announce our new Board of Directors. The new members are Brian Jenkins, General Robert "Doc" Foglesong, Frank Wren, and Thomas Payne. They are all committed to using their talents and influence to help make CDEX even more successful. Please visit our web site for all the bios of the new management team. We are also pleased to announce that Mr. Stephen McCommon will continue in his role as Chief Finance Office of the Company. In closing, we are extremely excited about the future of CDEX, and expect to be making more announcements very shortly.

About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, contact Jeff Brumfield at

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "believes," "should," "intends," and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

Contact Information